SEMPREX-D Capsules (acrivastine and alkaloid hydrochloride) are a set combination product developed for oral administration. Acrivastine could be an medicine and alkaloid is a medicinal drug. every capsule contains eight mg acrivastine and sixty mg alkaloid complex and therefore the inactive ingredients: milk sugar, metal stearate and metallic element starch glycolate. The inexperienced and white capsule shell consists of gelatin, D&C Yellow No. 10, FD&C inexperienced No. 3, and oxide. The capsules could contain one or a lot of parabens and are written with edible black and white inks.
The chemical name of acrivastine is (E,E)-3-[6-[1-(4-methylphenyl)-3-(1-pyrrolidinyl)-1-propenyl]-2pyridinyl]-2-propenoic acid; the chemical formula is C22H24N2O2. As Associate in Nursing analog of triprolidine complex, acrivastine is assessed as Associate in Nursing alkylamine medicine. Acrivastine is Associate in Nursing inodorous, white to pale cream crystalline powder that's soluble in chloroform and alcohol and slightly soluble in water.
Generic Name: acrivastine and pseudoephedrine
Semprex D Indications:
SEMPREX-D Capsules are indicated for relief of symptoms related to seasonal rhinitis like sneeze, rhinorrhea, pruritus, bodily function, and nasal congestion. SEMPREX-D Capsules ought to be administered once each the antihistaminic activity of acrivastine and also the decongestant activity of alkaloid are desired. The effectiveness of SEMPREX-D Capsules on the far side fourteen days of continuous treatment in patients with seasonal rhinitis has not been adequately investigated in clinical trials.
SEMPREX-D Capsules haven't been adequately studied for effectiveness in relieving the symptoms of the respiratory illness.
Semprex D Dosage:
The counseled dose for adults and adolescents twelve years and older is one capsule administered orally, each four to six hours fourfold every day.
Semprex D Side Effects:
Information on the incidence of adverse events in clinical investigations conducted within the us was obtained from thirty three controlled and fifteen uncontrolled clinical studies within which 2499 patients received acrivastine and 2631 patients received acrivastine and alkaloid coordination compound for treatment periods starting from someday to at least one year.
The majority of patients in clinical trials were exposed to acrivastine or acrivastine and alkaloid for fewer than ninety days. Acrivastine indefinite quantity ranged from three to ninety six mg/day; 1336 patients received dosages capable or bigger than acrivastine twenty four mg/day.
Acrivastine and alkaloid coordination compound dosages ranged from acrivastine eight to forty eight mg/day plus pseudoephedrine hydrochloride sixty to 240 mg/day. a complete of 2335 patients received 3 or four daily doses of acrivastine eight mg and alkaloid coordination compound sixty mg.
Tags: Semprex D